Historique
Bulletin de Périodique
Journal of Psychoactive Drugs , Vol.56, n°3 - July-August 2024
Paru le :
01/08/2024
Article en page(s) :
299-441
Langue(s) :
Anglais
Note de contenu :
CONTENTS:
- In Memoriam: Roland R. Griffiths (July 19, 1946-October 16, 2023). Henningfield J.E., Belouin S.J., Yaden D.B., Urrutia J., Anderson B.T., Berger A., et al., p. 299-300.
- Psilocybin's potential mechanisms in the treatment of depression: A systematic review. Lee H.J., Tsang V.W., Chai B.S., Lin M.C., Howard A., Uy C., et al., p. 301-315.
- Psychedelic experiences after bereavement improve symptoms of grief: The influence of emotional breakthroughs and challenging experiences. Low F., Earleywine M., p. 316-323.
- Health benefits and positive acute effects of psilocybin consumption: A quantitative textual analysis of user self-reported data. Bienemann B., Barbosa A.R., Cruz L., Multedo M., Mograbi D., p. 324-332.
- Associations between kratom-related state policy environments and kratom use in a nationally representative population in the United States. Ellis M.S., Buttram M.E., Forber A., Black J.C., p. 333-341.
- Sex moderates associations between dimensions of emotion dysregulation and problematic cannabis use. Cavalli J.M., Cservenka A., p. 342-352.
- Exclusive therapeutic use of cannabis in a large sample of daily cannabis users in France: A cross-sectional survey. Bastien M., Mezaache S., Donadille C., Martin V., Appel L., Lebrun M., et al., p. 353-363.
- Effectiveness of buprenorphine (naloxone) for opioid dependence does not differ across opioid categories: a retrospective cohort study from India. Ghosh A., Shaktan A., Basu D., Bn S., Naik S.S., Mattoo S.K., p. 364-372.
- Caregivers' attitudes toward treatment length for persons in Swedish opioid agonist treatment. A qualitative interview study. Nehlin C., Brander C.W., Öster C., p. 373-379.
- Pregabalin qualitative detection in Turkish forensic cases between 2017 to 2018. Teker C., Aslan R., Ipekçi C., Tokdemir M., Akgür S.A., p. 380-386.
- The effects of neighborhood disorder on polydrug use: Examining depressive symptoms and deviant peer association as mediating mechanisms. Wojciechowski T., p. 387-396.
- Risk and protective factors associated with drug use in healthcare professionals: A systematic review. Medina-Martinez J., Alino M., Vazquez-Martinez A., Villanueva-Blasco V.J., Cano-Lopez I., p. 397-411.
- Risk for ecstasy use disorder and other substance use among international users of recreational ecstasy/Molly/MDMA. Haug N.A., Wadekar R., Barry R., Sottile J., p. 412-421.
- Examining symptoms of stimulant misuse and community support among members of a recovery-oriented online community. Kasson E., Filiatreau L.M., Davet K., Kaiser N., Sirko G., Bekele M., et al., p. 422-432.
- Outcomes among sober living house residents who relapse: Role of recovery capital. Polcin D.L., Mahoney E., Witbrodt J., Subbaraman M., Mericle A.A., p. 433-441.
- In Memoriam: Roland R. Griffiths (July 19, 1946-October 16, 2023). Henningfield J.E., Belouin S.J., Yaden D.B., Urrutia J., Anderson B.T., Berger A., et al., p. 299-300.
- Psilocybin's potential mechanisms in the treatment of depression: A systematic review. Lee H.J., Tsang V.W., Chai B.S., Lin M.C., Howard A., Uy C., et al., p. 301-315.
- Psychedelic experiences after bereavement improve symptoms of grief: The influence of emotional breakthroughs and challenging experiences. Low F., Earleywine M., p. 316-323.
- Health benefits and positive acute effects of psilocybin consumption: A quantitative textual analysis of user self-reported data. Bienemann B., Barbosa A.R., Cruz L., Multedo M., Mograbi D., p. 324-332.
- Associations between kratom-related state policy environments and kratom use in a nationally representative population in the United States. Ellis M.S., Buttram M.E., Forber A., Black J.C., p. 333-341.
- Sex moderates associations between dimensions of emotion dysregulation and problematic cannabis use. Cavalli J.M., Cservenka A., p. 342-352.
- Exclusive therapeutic use of cannabis in a large sample of daily cannabis users in France: A cross-sectional survey. Bastien M., Mezaache S., Donadille C., Martin V., Appel L., Lebrun M., et al., p. 353-363.
- Effectiveness of buprenorphine (naloxone) for opioid dependence does not differ across opioid categories: a retrospective cohort study from India. Ghosh A., Shaktan A., Basu D., Bn S., Naik S.S., Mattoo S.K., p. 364-372.
- Caregivers' attitudes toward treatment length for persons in Swedish opioid agonist treatment. A qualitative interview study. Nehlin C., Brander C.W., Öster C., p. 373-379.
- Pregabalin qualitative detection in Turkish forensic cases between 2017 to 2018. Teker C., Aslan R., Ipekçi C., Tokdemir M., Akgür S.A., p. 380-386.
- The effects of neighborhood disorder on polydrug use: Examining depressive symptoms and deviant peer association as mediating mechanisms. Wojciechowski T., p. 387-396.
- Risk and protective factors associated with drug use in healthcare professionals: A systematic review. Medina-Martinez J., Alino M., Vazquez-Martinez A., Villanueva-Blasco V.J., Cano-Lopez I., p. 397-411.
- Risk for ecstasy use disorder and other substance use among international users of recreational ecstasy/Molly/MDMA. Haug N.A., Wadekar R., Barry R., Sottile J., p. 412-421.
- Examining symptoms of stimulant misuse and community support among members of a recovery-oriented online community. Kasson E., Filiatreau L.M., Davet K., Kaiser N., Sirko G., Bekele M., et al., p. 422-432.
- Outcomes among sober living house residents who relapse: Role of recovery capital. Polcin D.L., Mahoney E., Witbrodt J., Subbaraman M., Mericle A.A., p. 433-441.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |
Dépouillements
Ajouter le résultat à votre sélection
M. BASTIEN ;
S. MEZAACHE ;
C. DONADILLE ;
V. MARTIN ;
L. APPEL ;
M. LEBRUN ;
L. BRIAND MADRID ;
T. BARRÉ ;
P. ROUX
|
2024
Dans Journal of Psychoactive Drugs (Vol.56, n°3, July-August 2024) Article : Périodique
Dans Journal of Psychoactive Drugs (Vol.56, n°3, July-August 2024) Article : Périodique
Many cannabis users report therapeutic benefits from cannabis consumption, even when not recommended by a physician. To date, few data on therapeutic users of cannabis in France are available. Using a cross-sectional survey held in 2020, we coll[...]
Nouveauté
N. A. HAUG ;
R. WADEKAR ;
R. BARRY ;
J. SOTTILE
|
2024
Dans Journal of Psychoactive Drugs (Vol.56, n°3, July-August 2024) Article : Périodique
Dans Journal of Psychoactive Drugs (Vol.56, n°3, July-August 2024) Article : Périodique
Ecstasy/Molly/MDMA is a widely used substance often taken in combination with other drugs in different contexts. The current study assessed ecstasy use patterns, concurrent substance use and the context of ecstasy use among an international samp[...]